Savara Inc (SVRA) — 8-K Filings

8-K Filings (16)

• Savara Inc. Files 8-K: Material Definitive Agreement — Oct 30, 2025 Risk: medium
  On October 29, 2025, Savara Inc. entered into a Material Definitive Agreement. The filing also includes other events and financial statements and exhibits. Sava
• Savara Inc. Files 8-K: Material Agreement, FD Disclosure — Oct 29, 2025 Risk: medium
  On October 29, 2025, Savara Inc. filed an 8-K report detailing a material definitive agreement. The filing also included Regulation FD disclosures and other eve
• Savara Inc. Files 8-K with Financials and Exhibits — Sep 2, 2025 Risk: low
  On September 2, 2025, Savara Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine corporate disclosures
• Savara Inc. Files 8-K on Security Holder Vote — Jun 6, 2025 Risk: low
  On June 5, 2025, Savara Inc. filed an 8-K report detailing a submission of matters to a vote of security holders. The filing does not contain specific details r
• Savara Inc. Files 8-K, Notes Former Names — May 27, 2025 Risk: low
  On May 27, 2025, Savara Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." It also notes that Savar
• Savara Inc. Terminates Material Definitive Agreement — Mar 31, 2025 Risk: medium
  Savara Inc. announced on March 31, 2025, the termination of a material definitive agreement. The company, formerly known as Mast Therapeutics, Inc., is based in
• Savara Inc. Files 8-K: Agreement Termination & Financial Obligation — Mar 26, 2025 Risk: medium
  On March 26, 2025, Savara Inc. filed an 8-K report detailing the termination of a material definitive agreement and the creation of a direct financial obligatio
• Savara Inc. Announces Executive Changes — Jan 23, 2025 Risk: medium
  Savara Inc. announced on January 23, 2025, the departure of Dr. Robert L. Neville as Chief Medical Officer and the appointment of Dr. Claire Davies as interim C
• Savara Inc. Files 8-K Report — Jan 13, 2025 Risk: low
  On January 13, 2025, Savara Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 1717 Langhorne Newtown Road,
• Savara Inc. Files 8-K: Material Definitive Agreement — Jun 28, 2024 Risk: medium
  On June 27, 2024, Savara Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The company, formerly k
• Savara Inc. Files 8-K with Regulatory Updates — Jun 26, 2024 Risk: low
  On June 26, 2024, Savara Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing also includes financial statements and exhib
• Savara Inc. Files 8-K with Corporate Updates — Jun 7, 2024 Risk: low
  Savara Inc. filed an 8-K on June 7, 2024, reporting on events that occurred on June 6, 2024. The filing indicates changes to the company's articles of incorpora
• Savara Inc. Announces Material Agreement and Executive Changes — Apr 12, 2024 Risk: medium
  On April 10, 2024, Savara Inc. entered into a material definitive agreement. The company also reported the departure of directors or certain officers, the elect
• Savara Inc. Enters Material Definitive Agreement — Feb 16, 2024 Risk: medium
  Savara Inc. entered into a material definitive agreement on February 13, 2024, as reported in their 8-K filing. The filing indicates a significant corporate eve
• Savara Inc. Relocates Principal Executive Offices to Langhorne, PA — Jan 25, 2024
  Savara Inc. filed an 8-K on January 25, 2024, to report a change in its principal executive offices. The company's new address is 1717 Langhorne Newtown Road, S
• Savara Inc. Relocates Principal Executive Offices to Langhorne, PA — Jan 5, 2024
  Savara Inc. filed an 8-K on January 5, 2024, to update its principal executive offices from 6836 Bee Cave Road, Building 3, Suite 201, Austin, TX 78746 to 1717

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX